{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:12:21Z","timestamp":1789398741139,"version":"build-2803163510"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","award":["XZR2024198"],"award-info":[{"award-number":["XZR2024198"]}],"id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SYW2025077"],"award-info":[{"award-number":["SYW2025077"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108368","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:38:19Z","timestamp":1786322299000},"page":"108368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A data-driven atlas of CAR-based immunotherapy in lung cancer: Insights from multidatabase integration"],"prefix":"10.1016","volume":"231","author":[{"given":"Fangkai","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.phrs.2026.108368_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chinese medical journal"},{"issue":"7","key":"10.1016\/j.phrs.2026.108368_bib2","first-page":"640","volume":"383","author":"Howlader","year":"2020","journal-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality"},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189413","article-title":"Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochimica et biophysica acta. Reviews on cancer"},{"key":"10.1016\/j.phrs.2026.108368_bib4","article-title":"Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Frontiers in immunology"},{"issue":"10454","key":"10.1016\/j.phrs.2026.108368_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends in pharmacological sciences"},{"key":"10.1016\/j.phrs.2026.108368_bib7","volume":"13","author":"Zhang","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Molecular cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Molecular cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02648-z","article-title":"CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies","volume":"25","author":"Liu","year":"2026","journal-title":"Mol Cancer"},{"key":"10.1016\/j.phrs.2026.108368_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115010","article-title":"Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions","volume":"161","author":"Kouro","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.phrs.2026.108368_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291619","article-title":"Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils","volume":"14","author":"Liang","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.phrs.2026.108368_bib14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","article-title":"Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib15","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","article-title":"Engineering sonogenetic EchoBack-CAR T cells","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.phrs.2026.108368_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nature reviews. Clinical oncology"},{"issue":"7","key":"10.1016\/j.phrs.2026.108368_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102199","article-title":"EGFR TKIs suppress MUC1 glycosylation through the PI3K\/AKT\/SP1\/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell reports. Medicine"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib18","first-page":"2748","volume":"11","author":"Adusumilli","year":"2021","journal-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal transduction and targeted therapy"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib20","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","article-title":"Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles","volume":"16","author":"Xiao","year":"2025","journal-title":"Nature communications"},{"issue":"12","key":"10.1016\/j.phrs.2026.108368_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007426","article-title":"HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity","volume":"11","author":"Bassan","year":"2023","journal-title":"Journal for immunotherapy of cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.phrs.2026.108368_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1659848","article-title":"Research on Parkinson's disease immunotherapy: a bibliometric analysis via multiple databases","volume":"16","author":"Fei","year":"2025","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.phrs.2026.108368_bib24","article-title":"Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging trends","volume":"17","author":"Shi","year":"2026","journal-title":"Frontiers in immunology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib25","first-page":"392","volume":"110","author":"Arruda","year":"2022","journal-title":"VOSviewer and Bibliometrix"},{"key":"10.1016\/j.phrs.2026.108368_bib26","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA \u2026 Annual Symposium proceedings. AMIA Symposium"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib27","first-page":"197","volume":"18","author":"Galon","year":"2019","journal-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies"},{"key":"10.1016\/j.phrs.2026.108368_bib28","doi-asserted-by":"crossref","unstructured":"Siegel R.L., Miller K.D., Fuchs H.E., Jemal A.J.C.C.J.C.. Cancer statistics, 2022. 2022;72(1):7-33.","DOI":"10.3322\/caac.21708"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal transduction and targeted therapy"},{"issue":"7814","key":"10.1016\/j.phrs.2026.108368_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2026.108368_bib31","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nature biotechnology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Science China. Life sciences"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.phrs.2026.108368_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","article-title":"Targeting PD-L1 in non-small cell lung cancer using CAR T cells","volume":"9","author":"Liu","year":"2020","journal-title":"Oncogenesis"},{"issue":"16","key":"10.1016\/j.phrs.2026.108368_bib35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"21","key":"10.1016\/j.phrs.2026.108368_bib36","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"6230","key":"10.1016\/j.phrs.2026.108368_bib37","first-page":"124","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Cancer immunology"},{"key":"10.1016\/j.phrs.2026.108368_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"25","key":"10.1016\/j.phrs.2026.108368_bib39","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cellular & molecular immunology"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib41","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/2159-8290.CD-24-1515","article-title":"Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib42","doi-asserted-by":"crossref","first-page":"11593","DOI":"10.1038\/s41467-025-66737-1","article-title":"Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors","volume":"16","author":"Murray","year":"2025","journal-title":"Nat Commun"},{"issue":"7971","key":"10.1016\/j.phrs.2026.108368_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010073","article-title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","volume":"13","author":"Zhang","year":"2025","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.phrs.2026.108368_bib45","unstructured":"A Phase I\/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin. In: Bellicum P, United States Department of D, editors.; 2015."},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib48","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/2159-8290.CD-24-1515","article-title":"Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer discovery"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-025-01729-8","article-title":"Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide","volume":"18","author":"Kristmann","year":"2025","journal-title":"Journal of hematology & oncology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib50","doi-asserted-by":"crossref","first-page":"11593","DOI":"10.1038\/s41467-025-66737-1","article-title":"Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors","volume":"16","author":"Murray","year":"2025","journal-title":"Nature communications"},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib52","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","article-title":"Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity","volume":"29","author":"McKenna","year":"2021","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib54","doi-asserted-by":"crossref","first-page":"29436","DOI":"10.1038\/s41598-025-15086-6","article-title":"Co-expression of a truncated TGF\u03b2 receptor II in c-Met CAR T cells enhances antitumor activity against lung adenocarcinoma","volume":"15","author":"Su","year":"2025","journal-title":"Scientific reports"},{"issue":"9","key":"10.1016\/j.phrs.2026.108368_bib55","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14541","article-title":"Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer","volume":"28","author":"Li","year":"2023","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib56","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.scib.2024.12.001","article-title":"Dabrafenib upregulates hypoglycosylated MUC1 and improves the therapeutic efficacy of Tn-MUC1 CAR-T cells","volume":"70","author":"Zhou","year":"2025","journal-title":"Science bulletin"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood cancer journal"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell reports. Medicine"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib59","first-page":"473","volume":"38","author":"Hong","year":"2020","journal-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy"},{"key":"10.1016\/j.phrs.2026.108368_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib61","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"International journal of molecular sciences"},{"issue":"9","key":"10.1016\/j.phrs.2026.108368_bib62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nature biotechnology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-025-02383-x","article-title":"IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1\/-L1 therapy in SCLC","volume":"24","author":"Cui","year":"2025","journal-title":"Molecular cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108368_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009126","article-title":"Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer","volume":"12","author":"Wessel","year":"2024","journal-title":"Journal for immunotherapy of cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108368_bib65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-017-0238-6","article-title":"Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice","volume":"9","author":"Li","year":"2018","journal-title":"Cell death & disease"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","article-title":"Cancer-cell-secreted CXCL11 promoted CD8","volume":"7","author":"Gao","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12967-023-04206-3","article-title":"Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer","volume":"21","author":"Zheng","year":"2023","journal-title":"Journal of translational medicine"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib68","doi-asserted-by":"crossref","first-page":"694","DOI":"10.21037\/tlcr-23-820","article-title":"DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges","volume":"13","author":"Bellis","year":"2024","journal-title":"Translational lung cancer research"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"Journal for immunotherapy of cancer"},{"issue":"27","key":"10.1016\/j.phrs.2026.108368_bib70","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41388-018-0187-2","article-title":"Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models","volume":"37","author":"Crossland","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib71","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nature communications"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-017-0437-8","article-title":"Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells","volume":"10","author":"Qin","year":"2017","journal-title":"Journal of hematology & oncology"},{"issue":"8","key":"10.1016\/j.phrs.2026.108368_bib73","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/ijms18081677","article-title":"Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis","volume":"18","author":"Molfetta","year":"2017","journal-title":"International journal of molecular sciences"},{"key":"10.1016\/j.phrs.2026.108368_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107361","article-title":"The role of KIR positive NK cells in diseases and its importance in clinical intervention","volume":"92","author":"Dizaji Asl","year":"2021","journal-title":"International immunopharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib75","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"Journal of leukocyte biology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010699","article-title":"Genome-wide CRISPR\/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing","volume":"13","author":"Guia","year":"2025","journal-title":"Journal for immunotherapy of cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib77","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-023-41282-x","article-title":"Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment","volume":"14","author":"Wang","year":"2023","journal-title":"Nature communications"},{"issue":"Pt 2","key":"10.1016\/j.phrs.2026.108368_bib78","article-title":"SPSB1 inhibition induces cancer immune evasion by modulating the KLF6\/PD-L1 axis in non-small cell lung cancer cells","volume":"250","author":"Dong","year":"2026","journal-title":"Biochemical pharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib79","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ccell.2025.12.021","article-title":"Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth","volume":"44","author":"Mateus-Tique","year":"2026","journal-title":"Cancer cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib80","doi-asserted-by":"crossref","first-page":"678","DOI":"10.21037\/tlcr-23-793","article-title":"Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells","volume":"13","author":"Mazza","year":"2024","journal-title":"Translational lung cancer research"},{"key":"10.1016\/j.phrs.2026.108368_bib81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2020.04.016","article-title":"A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis","volume":"122","author":"Lu","year":"2020","journal-title":"Molecular immunology"},{"key":"10.1016\/j.phrs.2026.108368_bib82","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell transplantation"},{"issue":"9","key":"10.1016\/j.phrs.2026.108368_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2005046","article-title":"The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation","volume":"16","author":"Knoblich","year":"2018","journal-title":"PLoS biology"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib84","first-page":"11317","volume":"148","author":"Dai","year":"2026","journal-title":"NIR-II Nanomedicine Engineered CAR-NK Cells for Precision Navigation and Potentiating Lung Cancer Immunotherapy by Remodeling Tumor Microenvironment"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib85","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.7150\/thno.127565","article-title":"One-step knock-in CAR constructs in human NK cells enable scalable, TGF\u03b21-resistant immunotherapy for solid tumors","volume":"16","author":"Yee","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.108368_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1704404","article-title":"Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks","volume":"16","author":"Baughan","year":"2025","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.phrs.2026.108368_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115577","article-title":"Expression of membrane-bound Interleukin-15 sustains the growth and survival of CAR-NK cells","volume":"166","author":"Feng","year":"2025","journal-title":"International immunopharmacology"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib88","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00262-025-04191-0","article-title":"CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor","volume":"74","author":"Kogue","year":"2025","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib89","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends in immunology"},{"issue":"19","key":"10.1016\/j.phrs.2026.108368_bib90","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1097\/CM9.0000000000003803","article-title":"Strategies and challenges in promoting chimeric antigen receptor T cells trafficking and infiltration of solid tumors","volume":"138","author":"Wang","year":"2025","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib91","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2026.108368_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108586","article-title":"Targeting CAFs and extracellular matrix (ECM) in lung cancer: Potential of adjuvants and nanoparticles","volume":"162","author":"Feng","year":"2025","journal-title":"Bioorg Chem"},{"issue":"46","key":"10.1016\/j.phrs.2026.108368_bib93","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2522634122","article-title":"Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors","volume":"122","author":"Hadjigeorgiou","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2026.108368_bib94","doi-asserted-by":"crossref","first-page":"0023","DOI":"10.34133\/cancomm.0023","volume":"46","author":"An","year":"2026","journal-title":"Cancer communications (London, England)"},{"issue":"12","key":"10.1016\/j.phrs.2026.108368_bib95","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nature immunology"},{"issue":"7750","key":"10.1016\/j.phrs.2026.108368_bib96","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002980","article-title":"Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity","volume":"9","author":"Zhang","year":"2021","journal-title":"Journal for immunotherapy of cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12951-023-01900-8","article-title":"CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach","volume":"21","author":"Zhang","year":"2023","journal-title":"Journal of nanobiotechnology"},{"key":"10.1016\/j.phrs.2026.108368_bib99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2021.10.041","article-title":"A highly-specific fully-human antibody and CAR-T cells targeting CD66e\/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo","volume":"525","author":"Baek","year":"2022","journal-title":"Cancer letters"},{"issue":"10495","key":"10.1016\/j.phrs.2026.108368_bib100","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib101","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.phrs.2026.108368_bib102","article-title":"Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy","volume":"17","author":"Zhang","year":"2026","journal-title":"Frontiers in immunology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib103","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1186\/s12967-024-05724-4","article-title":"Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma","volume":"22","author":"Lin","year":"2024","journal-title":"Journal of translational medicine"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2024.200777","article-title":"Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells","volume":"32","author":"Yoon","year":"2024","journal-title":"Molecular therapy. Oncology"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol Sci"},{"issue":"19","key":"10.1016\/j.phrs.2026.108368_bib106","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell."},{"key":"10.1016\/j.phrs.2026.108368_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100870","article-title":"cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol Aspects Med"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib108","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib109","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med."},{"issue":"10495","key":"10.1016\/j.phrs.2026.108368_bib110","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib111","article-title":"CD4(+) anti-TGF-beta CAR T cells and CD8(+) conventional CAR T cells exhibit synergistic antitumor effects","volume":"6","author":"Zheng","year":"2025","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib112","article-title":"Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep Med"},{"issue":"22","key":"10.1016\/j.phrs.2026.108368_bib113","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1158\/1078-0432.CCR-25-1693","article-title":"The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells","volume":"31","author":"Yang","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.phrs.2026.108368_bib114","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1200\/JCO.23.02668","article-title":"Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC)","volume":"42","author":"Pike","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib115","doi-asserted-by":"crossref","first-page":"35784","DOI":"10.1002\/cncr.35784","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions","volume":"131 1","author":"Desilets","year":"2025","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108368_bib116","article-title":"MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer","volume":"6","author":"Del Rey-Vergara","year":"2025","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib117","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.scib.2024.12.001","article-title":"Dabrafenib upregulates hypoglycosylated MUC1 and improves the therapeutic efficacy of Tn-MUC1 CAR-T cells","volume":"70","author":"Zhou","year":"2025","journal-title":"Sci Bull (Beijing)"},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2026-014991","article-title":"VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC","volume":"14","author":"Roulleaux-Dugage","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib119","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1753465816652083","article-title":"Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience","volume":"10","author":"Greillier","year":"2016","journal-title":"Ther Adv Respir Dis"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib120","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108368_bib121","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.ircmb.2024.07.003","article-title":"Tumor microenvironment induced switch to mitochondrial metabolism promotes suppressive functions in immune cells","volume":"389","author":"Pandey","year":"2024","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib122","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","article-title":"The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS(G12D)-driven non-small cell lung cancer","volume":"23","author":"McDaid","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.phrs.2026.108368_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.179157","article-title":"A derivative of cytisine N-isoflavone from Sophora alopecuroides L., suppresses non-small cell lung cancer by targeting mTOR","volume":"1031","author":"He","year":"2026","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib124","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3892\/or.2012.1855","article-title":"Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells","volume":"28","author":"Miyake","year":"2012","journal-title":"Oncol Rep"},{"issue":"12","key":"10.1016\/j.phrs.2026.108368_bib125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010312","article-title":"AMPK agonism optimizes the in vivo activation and antileukemic efficacy of chimeric antigen receptor T cells","volume":"13","author":"Braverman","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.phrs.2026.108368_bib126","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1038\/s44319-025-00640-0","article-title":"CTRP9 engages AdipoR1 and promotes T cell glycolysis and immunity","volume":"26","author":"Li","year":"2025","journal-title":"EMBO Rep"},{"key":"10.1016\/j.phrs.2026.108368_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-014327","article-title":"HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence","volume":"14","author":"Zhang","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2026.108368_bib128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010077","article-title":"HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1\/JAK1\/FGL1 axis in lung adenocarcinoma","volume":"12","author":"Xu","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13402-024-00989-9","article-title":"Low-dose SAHA enhances CD8(+) T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer","volume":"48","author":"Dong","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17501911.2026.2637418","article-title":"DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions","volume":"18","author":"Michael","year":"2026","journal-title":"Epigenomics."},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib131","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ijc.34783","article-title":"Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment","volume":"154","author":"Pelos","year":"2024","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2005.02.002","article-title":"DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results","volume":"55","author":"Digel","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib133","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.phrs.2026.108368_bib134","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neo.2020.12.006","article-title":"Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment","volume":"23","author":"Gong","year":"2021","journal-title":"Neoplasia."},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.phrs.2026.108368_bib136","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/OTT.S341179","article-title":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives","volume":"16","author":"Maher","year":"2023","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.phrs.2026.108368_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.903562","article-title":"Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer","volume":"13","author":"Kandra","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.phrs.2026.108368_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782775","article-title":"Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.phrs.2026.108368_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32020079","article-title":"Tumor-Associated Extracellular Matrix Obstacles for CAR-T Cell Therapy: Approaches to Overcoming","volume":"32","author":"Klabukov","year":"2025","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-024-03027-6","article-title":"Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening","volume":"43","author":"Li","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib141","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.phrs.2026.108368_bib142","article-title":"Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib143","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T cells for Cancer Immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib144","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.phrs.2026.108368_bib145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2024.2371034","article-title":"Small molecule-regulated switches to provide functional control of CAR T cells within the patient","volume":"24","author":"Zajc","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"17","key":"10.1016\/j.phrs.2026.108368_bib146","doi-asserted-by":"crossref","first-page":"70069","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer."},{"issue":"7","key":"10.1016\/j.phrs.2026.108368_bib147","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.phrs.2026.108368_bib148","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib149","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"7952","key":"10.1016\/j.phrs.2026.108368_bib150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.phrs.2026.108368_bib151","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1089\/hum.2017.243","article-title":"Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy","volume":"29","author":"Siegler","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.phrs.2026.108368_bib152","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108368_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.resinv.2026.101434","article-title":"Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance","volume":"64","author":"Nishii","year":"2026","journal-title":"Respir Investig"},{"issue":"13","key":"10.1016\/j.phrs.2026.108368_bib154","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1158\/1078-0432.CCR-25-4159","article-title":"Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells","volume":"32","author":"Vista","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2026.108368_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106329","article-title":"Locoregional delivery of CAR-T cells in the clinic","volume":"182","author":"Sagnella","year":"2022","journal-title":"Pharmacological research"},{"issue":"2","key":"10.1016\/j.phrs.2026.108368_bib156","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer cell"},{"issue":"559","key":"10.1016\/j.phrs.2026.108368_bib157","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Science translational medicine"},{"issue":"9","key":"10.1016\/j.phrs.2026.108368_bib158","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","article-title":"Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib159","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Molecular cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108368_bib160","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jcyt.2024.03.484","article-title":"Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers","volume":"26","author":"Russell","year":"2024","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.phrs.2026.108368_bib161","first-page":"1390","volume":"29","author":"Clubb","year":"2023","journal-title":"Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes"},{"issue":"4","key":"10.1016\/j.phrs.2026.108368_bib162","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.ymthe.2025.02.035","article-title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells","volume":"33","author":"Wachsmann","year":"2025","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"7952","key":"10.1016\/j.phrs.2026.108368_bib163","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108368_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218257","article-title":"Programmable Smart CAR-T design: A new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence","volume":"640","author":"Wen","year":"2026","journal-title":"Cancer letters"},{"issue":"7643","key":"10.1016\/j.phrs.2026.108368_bib165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108368_bib166","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-026-04425-w","article-title":"CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions","author":"Bach","year":"2026","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.phrs.2026.108368_bib167","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108368_bib168","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41419-024-06940-y","article-title":"Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer","volume":"15","author":"Izumi","year":"2024","journal-title":"Cell Death Dis"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:58:39Z","timestamp":1789397919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":164,"alternative-id":["S1043661826002835"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108368","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A data-driven atlas of CAR-based immunotherapy in lung cancer: Insights from multidatabase integration","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108368"}}